{"id":30436,"date":"2020-11-11T18:40:29","date_gmt":"2020-11-11T18:40:29","guid":{"rendered":"https:\/\/amelie-project.eu\/?post_type=press-release&p=30436"},"modified":"2021-05-08T07:38:26","modified_gmt":"2021-05-08T07:38:26","slug":"la-ue-respalda-una-investigacion-pionera-sobre-la-incontinencia-con-una-financiacion-de-95-millones-de-euros","status":"publish","type":"press-release","link":"https:\/\/amelie-project.eu\/es\/comunicado-de-prensa\/la-ue-respalda-una-investigacion-pionera-sobre-la-incontinencia-con-una-financiacion-de-95-millones-de-euros\/","title":{"rendered":"La UE financia con 9,5 millones de euros una investigaci\u00f3n pionera sobre la incontinencia"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.6.3″ custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.6.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” module_alignment=”center” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.6.3″ text_font=”Gotham kinda bold||||||||” text_text_color=”#000000″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”]<\/p>\n

La UE ha concedido 9,5 millones de euros a un innovador proyecto de investigaci\u00f3n sobre el tratamiento de la incontinencia fecal.<\/p>\n

El objetivo de la investigaci\u00f3n es utilizar una terapia celular revolucionaria para encontrar una posible cura a una enfermedad que afecta a unos 67 millones de personas en Europa.<\/p>\n

La financiaci\u00f3n se destinar\u00e1 a un consorcio de 13 organizaciones de nueve pa\u00edses denominado AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n

El proyecto estar\u00e1 coordinado por la UCL y dirigido por Richard Day, catedr\u00e1tico de Tecnolog\u00eda de Medicina Regenerativa de la UCL.<\/p>\n

Otros socios en el Reino Unido son la Universidad Queen Mary de Londres, NHS Blood and Transplant y la organizaci\u00f3n ben\u00e9fica Bowel Research UK, que liderar\u00e1 la participaci\u00f3n de los pacientes.<\/p>\n

La investigaci\u00f3n se llevar\u00e1 a cabo a lo largo de cinco a\u00f1os, con instituciones distintas en el Reino Unido, Espa\u00f1a y Portugal asumiendo el liderazgo en cada nueva etapa.<\/p>\n

El proyecto se centrar\u00e1 en tomar c\u00e9lulas musculares del propio paciente, cargarlas en microportadores especialmente dise\u00f1ados e implantarlas en el m\u00fasculo da\u00f1ado para favorecer su regeneraci\u00f3n y restablecer su funci\u00f3n normal.<\/p>\n

El profesor Day afirm\u00f3 que esta terapia de medicina regenerativa ofrece esperanzas a muchas personas cuya vida se ve gravemente afectada por la incontinencia:<\/p>\n

\u201cEstamos tremendamente entusiasmados con la perspectiva del proyecto AMELIE y los beneficios potenciales que pueden derivarse del nuevo enfoque terap\u00e9utico que se est\u00e1 investigando.<\/p>\n

\u201cEstamos impacientes por trabajar con el excepcional consorcio de acad\u00e9micos, m\u00e9dicos, industriales y organizaciones ben\u00e9ficas de toda Europa para desarrollar nuestro enfoque pionero de medicina regenerativa para el tratamiento de esta enfermedad debilitante\".<\/p>\n

\u201cSer\u00e1 un planteamiento radical e innovador nunca antes intentado a tal escala\u201d.\u201d<\/p>\n

Lesley Booth MBE, Directora de Investigaci\u00f3n y PPI de Bowel Research UK, afirm\u00f3 que, aunque la enfermedad es extremadamente com\u00fan, no se habla mucho de ella.<\/p>\n

\u201cLa realidad de vivir con incontinencia fecal puede ser devastadora. No cabe duda de que limita la vida. Y el hecho de que sea una afecci\u00f3n de la que la gente no habla libremente no hace sino aumentar las dificultades para llevar una vida normal\u201d, afirma.<\/p>\n

\u201cEncontrar una terapia que funcione no s\u00f3lo ser\u00eda un gran avance m\u00e9dico, sino que cambiar\u00eda la vida de millones de personas\u201d.\u201d<\/p>\n

Este proyecto ha recibido financiaci\u00f3n del programa de investigaci\u00f3n e innovaci\u00f3n Horizonte 2020 de la Uni\u00f3n Europea en virtud del acuerdo de subvenci\u00f3n n\u00ba 874807.<\/p>\n

\n

<\/p>\n

[\/et_pb_text][et_pb_image src=”https:\/\/amelie-project.eu\/wp-content\/uploads\/2021\/01\/Picture-1.png” title_text=”Picture 1″ _builder_version=”4.6.3″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence. The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE). The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL. Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement. The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage. The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function. Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence: \u201cWe are tremendously excited by the prospect of the AMELIE project […]<\/p>","protected":false},"featured_media":31025,"template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\n

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence.<\/p>\n\n\n\n

The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. <\/p>\n\n\n\n

The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n\n\n\n

The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL.<\/p>\n\n\n\n

Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement.<\/em><\/p>\n\n\n\n

The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage.<\/p>\n\n\n\n

The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function.<\/p>\n\n\n\n

Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence:<\/p>\n\n\n\n

\u201cWe are tremendously excited by the prospect of the AMELIE project and the potential benefits that may arise from the new therapeutic approach being investigated.<\/p>\n\n\n\n

\u201cWe look forward to working with the exceptional consortium of academics, clinicians, industry and charity partners from across Europe to develop our pioneering regenerative medicine approach for treating this debilitating condition.<\/p>\n\n\n\n

\u201cThis will be a radical and innovative approach never before attempted at such a scale.\u201d<\/p>\n\n\n\n

Lesley Booth MBE, Director of Research and PPI at Bowel Research UK, said that, whilst the condition is extremely common, it is not much talked about.<\/p>\n\n\n\n

\u201cThe reality of living with faecal incontinence can be devastating. It is definitely life-limiting. And the fact that it\u2019s a condition which people don\u2019t discuss freely just adds to the difficulties of leading a normal life,\u201d she said.<\/p>\n\n\n\n

\u201cFinding a therapy which works would not just be a major medical breakthrough, it would be life-changing for millions.\u201d<\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

Ends<\/strong><\/p>\n\n\n\n

NOTES TO EDITORS<\/strong><\/p>\n\n\n\n

AMELIE<\/strong> (Anchored Muscle cELls for IncontinencE consortium) is made up of the following: University College London, Instituto Superior Tecnico (Portugal), Queen Mary University of London, Medical University of Graz (Austria), Aarhus University Hospital (Denmark), Rouen University Hospital (France), University Hospital Erlangen (Germany), Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (Spain), NHS Blood and Transplant (UK), Polysciences Europe GmbH (Germany), Ttopstart (Netherlands), Bowel Research (UK), Consorzio per Valutazioni Biologiche e Farmacologiche (Italy).<\/p>\n\n\n\n

Horizon 2020<\/strong> is an EU funding programme for research and innovation. It is the biggest EU Research and Innovation programme ever with nearly \u20ac80 billion of funding available over 7 years (2014 to 2020) \u2013 in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. https:\/\/ec.europa.eu\/programmes\/horizon2020\/en\/what-horizon-2020<\/a><\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

AMELIE contact:<\/strong><\/p>\n\n\n\n

Media contact:<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n","_et_gb_content_width":"","_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_links_to":"","_links_to_target":""},"categories":[51],"class_list":["post-30436","press-release","type-press-release","status-publish","has-post-thumbnail","hentry","category-press-release"],"_links":{"self":[{"href":"https:\/\/amelie-project.eu\/es\/wp-json\/wp\/v2\/press-release\/30436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amelie-project.eu\/es\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/amelie-project.eu\/es\/wp-json\/wp\/v2\/types\/press-release"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amelie-project.eu\/es\/wp-json\/wp\/v2\/media\/31025"}],"wp:attachment":[{"href":"https:\/\/amelie-project.eu\/es\/wp-json\/wp\/v2\/media?parent=30436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amelie-project.eu\/es\/wp-json\/wp\/v2\/categories?post=30436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}